Estradiol Patches for Bone Health: Label Doses and Trial Evidence

Estradiol patches can prevent postmenopausal bone loss, and some have an FDA indication for preventing postmenopausal osteoporosis. Prevention is not the same as treating established osteoporosis. A patch’s labeled dose, its measured effect on bone mineral density (BMD), and evidence that it prevents fractures answer different questions.

What the product labels say

Menostar delivers 14 micrograms of estradiol daily and is changed weekly. Its indication is osteoporosis prevention—not hot-flash relief or treatment of established osteoporosis. When estrogen is considered solely for prevention, its label advises considering non-estrogen medicines first and reserving estrogen for women at significant osteoporosis risk. [1]

Vivelle-Dot’s labeled starting dose for osteoporosis prevention is 0.025 mg/day, with patches changed twice weekly and adjustment according to clinical response. Its hot-flash starting dose, 0.0375 mg/day, is different. Climara is an estradiol-only patch changed once weekly; its prevention dosing is also individualized according to clinical response. [2,3]

These distinctions do not establish identical BMD outcomes between brands or equivalence to an oral estrogen dose. There is no universal 0.05 mg/day “bone dose,” and a trial result does not justify automatic escalation.

What patch trials measured

Ettinger’s two-year randomized trial compared 14 micrograms/day with placebo in 417 postmenopausal women aged 60–80, with intact uteruses and BMD z scores ≥−2.0. Both groups received calcium and vitamin D. [4]

The differences are calculated by subtracting placebo change from estradiol change. They describe BMD percentage points, rather than fracture-risk reductions. This trial does not establish treatment efficacy for established osteoporosis. The unopposed-estrogen trial reported one endometrial hyperplasia case with estradiol and none with placebo; its design does not select a progesterone regimen. [4]

A separate 24-month randomized trial tested a seven-day patch delivering 0.025, 0.05, 0.06 or 0.1 mg/day. All four doses produced significantly better spine and hip BMD results than placebo. The findings do not identify 0.05 mg/day as universally best, demonstrate steadily greater benefit with each higher dose, or establish fracture efficacy. [5]

Choosing therapy means assessing fracture risk

The Endocrine Society recommends bisphosphonates as first-line treatment for postmenopausal women at high fracture risk. It suggests menopausal hormone therapy for selected women who are under 60 or within 10 years of menopause, have low clot risk and bothersome menopausal symptoms, cannot appropriately use bisphosphonates or denosumab, have no relevant contraindications, and are willing to use hormones. This guideline suggestion does not create a patch FDA treatment indication. [6]

Clinical decisions therefore consider fracture history, DXA findings, other risks, symptoms and available medicines—not age or patch strength alone.

Low bone density or osteopenia does not, by itself, select a patch as the preferred medicine. Clarify whether the plan addresses menopausal symptoms, bone-loss prevention or treatment of fracture risk. Comparing BMD percentages from separate studies cannot supply a head-to-head treatment choice.

When discussing a move to another bone medicine, confirm the exact drug, start and stop instructions, and planned reassessment with the prescriber. A hormone-therapy stop does not establish an automatic alendronate or denosumab prescription. [6,9]

Fracture evidence and continued use

Hormone therapy has evidence for preventing bone loss and fractures, but the trials above measured patch-specific BMD outcomes. WHI found fracture benefit and other health risks with oral conjugated equine estrogens plus medroxyprogesterone acetate. Its outcome percentages cannot simply be assigned to an estradiol patch with micronized progesterone. [7,8]

Transdermal delivery and lower doses may reduce clot and stroke risk, but do not eliminate estrogen-related risks. Continued use requires individualized, periodic benefit–risk reassessment, not an automatic age cutoff or five-year stop. If therapy stops, reassess ongoing bone protection rather than automatically prescribing another drug. [7,9]

The adult patch guide compares named-product strengths and replacement schedules. Progesterone planning with an estradiol patch explains the separate endometrial-protection question.

References

1. DailyMed. Menostar—estradiol transdermal system: prescribing information. Updated March 12, 2026.
2. DailyMed. Vivelle-Dot—estradiol transdermal system: prescribing information.
3. DailyMed. Climara—estradiol transdermal system: prescribing information.
4. Ettinger B, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104(3):443–451.
5. Weiss SR, et al.; Transdermal Estradiol Investigator Group. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gynecol. 1999;94(3):330–336.
6. Endocrine Society. Pharmacological management of osteoporosis in postmenopausal women. Clinical practice guideline; see recommendations 2.1 and 6.1.
7. The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794. Official society reprint.
8. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
9. Greendale GA, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the PEPI Safety Follow-up Study. Arch Intern Med. 2002;162(6):665–672.